Evidence map›Paper›PMID 41871874›Full record

GuidelineJournal for immunotherapy of cancer2026

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Rana R McKay, Archana Ajmera, Michael B Atkins, Pedro C Barata, Cristiane Bergerot, Laura Bukavina, Toni K Choueiri, Arpita Desai, A Ari Hakimi, Susan Poteat and 9 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rana R McKayDepartments of Medicine and Urology, University of California San Diego, La Jolla, California, USA rmckay@health.ucsd.edu.
Archana AjmeraDepartment Hematology-Oncology, University of California San Diego, La Jolla, California, USA.
Michael B AtkinsDepartment of Oncology, Georgetown University Medical Center, Washington, District of Columbia, USA.ORCID http://orcid.org/0000-0003-3901-9924
Pedro C BarataDepartment of Internal Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.ORCID http://orcid.org/0000-0002-8890-2951
Cristiane BergerotDepartment of Supportive Care, Oncoclinicas and Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Sao Paulo, Brazil.
Laura BukavinaDepartment of Urology, Cleveland Clinic Glickman Urological Institute, Cleveland, Ohio, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0002-9201-3217
Arpita DesaiDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
A Ari HakimiDepartment of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Susan PoteatKidneyCAN, Beavercreek, Ohio, USA.
Thomas PowlesBarts Cancer Institute, Queen Mary University of London, London, Greater London, UK.
Brian I RiniDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID http://orcid.org/0000-0002-2212-080X
Brian ShuchDepartment of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Shankar SivaSir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Wenxin XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Wesley YipDepartment of Surgery, City of Hope, Duarte, California, USA.
Tian ZhangDepartment of Internal Medicine, Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID http://orcid.org/0000-0001-8914-3531
Sumanta K PalDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.ORCID http://orcid.org/0000-0002-1712-0848

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More recently, ICIs are also being used in the adjuvant setting for high-risk patients. However, treatment with ICIs requires a nuanced understanding of topics such as patient selection, histology and risk considerations, and integration with local therapies. As such, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline (CPG) on immunotherapy for the treatment of RCC. Drawing from published data and clinical experience, the Expert Panel developed evidence-based and consensus-based recommendations. Topics include therapy selection in the adjuvant and metastatic settings, considerations for special patient populations, response monitoring, and patient education and quality of life considerations, among others, with the goal of improving patient care by providing guidance to the oncology community.

Indexed as

Carcinoma, Renal CellImmune Checkpoint InhibitorsImmunotherapyKidney NeoplasmsHumansImmune Checkpoint InhibitorsAdjuvantCombination therapyImmune Checkpoint InhibitorQuality of life - QOLRenal Cell Carcinoma

Identifiers

PMID41871874
PMCPMC13034276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.